Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Orexigen Resurrects Contrave With New Trial Agreement With FDA

This article was originally published in The Pink Sheet Daily

Executive Summary

The biotech breathes new life into its obesity program now that it has reached agreement with FDA on a two-year cardiovascular safety study for Contrave.
Advertisement

Related Content

Lorcaserin Safety Questions Can Be Answered In Post-Market Study, Panel Tells FDA
With SPA Finalized, Orexigen To Begin CV Outcomes Study For Contrave In Second Quarter
Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
Regulatory Update For Qnexa Could Signal A Change In The Obesity Landscape
Orexigen Agreement On Contrave CV Trial Hints At FDA’s Thinking On Obesity
FDA Calls For Pre-Market CV Safety Trials For Some Constipation Drugs
Vivus Will Cut Population In Qnexa Resubmission
Arena Gains Evidence To Address FDA Concerns About Lorcaserin, But More Still Needed
Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk
Obesity Drugs Go Back To The Drawing Board; FDA To Hold Advisory Cmte On CV Risk

Topics

Advertisement
UsernamePublicRestriction

Register

PS072799

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel